A structure-function approach to optimizing TLR4 ligands for human vaccines

por Carter, Darrick, Fox, Christopher B, Day, Tracey A, Guderian, Jeffrey A, Liang, Hong, Rolf, Tom, Vergara, Julie, Sagawa, Zachary K, Ireton, Greg, Orr, Mark T, Desbien, Anthony, Duthie, Malcolm S, Coler, Rhea N, Reed, Steven G
Publicado 2016

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial

por Coler, Rhea N., Day, Tracey A., Ellis, Ruth, Piazza, Franco M., Beckmann, Anna Marie, Vergara, Julie, Rolf, Tom, Lu, Lenette, Alter, Galit, Hokey, David, Jayashankar, Lakshmi, Walker, Robert, Snowden, Margaret Ann, Evans, Tom, Ginsberg, Ann, Reed, Steven G.
Publicado 2018

Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults

por Sagawa, Zachary K., Goman, Cristina, Frevol, Aude, Blazevic, Azra, Tennant, Janice, Fisher, Bridget, Day, Tracey, Jackson, Stephen, Lemiale, Franck, Toussaint, Leon, Kalisz, Irene, Jiang, Joe, Ondrejcek, Lisa, Mohamath, Raodoh, Vergara, Julie, Lew, Alan, Beckmann, Anna Marie, Casper, Corey, Hoft, Daniel F., Fox, Christopher B.
Publicado 2023